PPARG and diabetes mellitus: Thiazolidinediones (TZDs) - strong synthetic PPARγ agonists used in diabetes therapy to improve insulin sensitivity - induce weight gain (reviewed in [39]) whereas CLAs, natural PPARγ ligands, caused moderate weight loss in humans [4,40] and in some studies reduced insulin sensitivity in an isomer specific way [41,42].